Small-series manufacturing
When your diagnostic instrument is too specialized for mass production — and too critical to compromise — structured small-series manufacturing becomes essential.
dg technologies provides compliant, precision small- to mid-series manufacturing for opto-electronic diagnostic systems. We operate in the critical phase between engineering validation and full industrial scale — where technical discipline, flexibility, and manufacturing insight matter most.
Opto-electronic diagnostic devices are inherently demanding systems. Optical alignment must be precise and stable. Mechanical tolerances must be controlled. Electronic integration must be robust. Documentation must be complete and traceable.
Large manufacturers are optimized for efficiency at scale. Their infrastructure, cost structures, and internal processes are designed for high-volume output. Small batches of technically complex instruments rarely fit this model.
Yet clinical validation units, pilot systems, early customer deployments, and bridge production runs are indispensable steps in the lifecycle of a diagnostic product. They require structured manufacturing — but not mass production. This is the gap we fill.
At dg technologies, small-series manufacturing typically covers production volumes between 10 and 300 units per batch.
Within this range, we can operate economically while maintaining the precision, documentation discipline, and technical oversight required for opto-electronic diagnostic systems.
We assemble and integrate opto-mechanical, electronic, and mechanical subsystems in controlled environments. Optical paths are aligned and verified. Illumination systems are integrated and calibrated. Electronics are installed, connected, and functionally validated. Each instrument passes through defined testing and documentation stages before release.
The result is not merely a completed device, but a structured and traceable production unit ready for clinical, validation, or early market use.
Our focus is not general contract manufacturing. It is precision integration of complex optical diagnostic platforms.
Let’s discuss where you are in your development journey.
Small-series manufacturing requires a fundamentally different model than high-volume production.
We do not compete with high-volume manufacturers. We complement them by ensuring that products reach industrial maturity before scale begins.
| Aspect | dg technologies GmbH | Large CDMO |
|---|---|---|
| Typical batch size | 10–300 units | 5,000+ units |
| Economic logic | Low-volume viability | Scale efficiency |
| Engineering access | Direct technical interaction | Layered communication |
| Adaptability | Fast process adjustments | Formal change processes |
| Complex, non-standard builds | Core competence | Often deprioritized |
| Scale transfer | Structured preparation | Native mass production |
Bringing an opto-electronic diagnostic instrument to market is a structured progression — from engineering feasibility to validated production and ultimately to scale. Each phase has distinct objectives. We support the most critical transition stages.
Executed by dg technologies GmbH
In this phase, concepts are transformed into robust, functional instruments.Typical activities include prototype builds, optical alignment validation, integration refinement, and definition of testing strategies. The objective is technical reliability and early manufacturability. dg technologies GmbH supports and executes this phase with a strong focus on structured engineering and production readiness. Find out more.
Executed by dg technologies GmbH
This phase bridges development and industrial scale. Assembly workflows are formalized, calibration procedures standardized, and unit-level traceability implemented. Process stability and documentation maturity are established. The goal is manufacturing readiness — supporting clinical validation, pilot launches, and early market entry. Small-series production is not a temporary workaround.
It is a controlled industrialization step.
Typically executed by large CDMOs
Once clinical success and market demand justify scale, production transitions into a high-volume setting.
Because Phases 1 and 2 were executed with manufacturability and documentation discipline in mind, the transfer into high-volume production becomes significantly smoother and lower risk. Scale is no longer a leap — it is a structured progression.
Imagine a diagnostic company preparing for clinical validation of a new optical reader. The required volume is approximately 120 units — too small to be economically viable for a high-volume manufacturing partner.
In such a case, we would structure a dedicated small-series production workflow, implement defined optical calibration procedures, ensure full traceability, and deliver all units within the required validation timeline.
The result: a controlled, documented production process that not only supports clinical validation but also prepares the foundation for a smooth transfer to high-volume manufacturing after clinical success.
Small-series manufacturing becomes a strategic bridge — not a temporary workaround.
If you are planning a small-series production run, an early technical discussion is the most efficient next step.
Share your instrument type, target volume, timeline, and regulatory framework. We will define a structured manufacturing approach aligned with your scale strategy.
